If you liked this article you might like

Gene Editing Company Joins NASDAQ, Jumps Over 20% on First Day
Move Over GMO's: IPO for Gene Editor Calyxt Launches Next Week
Cellectis Gains FDA Nod to Test New Gene-Edited Cancer Treatment